ARCT News and Press, Arcturus Therapeutics Ltd. From 02/19/21

Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare d...

Arcturus Therapeutics ([[ARCT]] -1.9%) is on course to record what could become its longest losing streak since early September 2020 as B. Riley Securities downgrades the stock once more to Sell from Neutral.The analyst Mayank Mamtani has also lowered the 12-month price target to $45.00 from ...

ARCT peaked and then slumped in recent weeks as investors lost interest in its coronavirus vaccine. Promising platform and advantages suggests this is a worthwhile holding. Upside price target (of a double) discussed but depends on vaccine approval. For further details see: ...

B.Riley Securities downgrades Arcturus Therapeutics ([[ARCT]] +14.4%) to Neutral from Buy, owing to the company's ARCT-021 Phase I/II interim data coming up short against the recently published early-stage data from Johnson & Johnson ([[JNJ]] +1.1%) for its COVID-19 vaccine candidate...

Looking For The Best Biotech Stocks To Watch? 3 To Consider Biotech stocks have been and still are on a tear in the stock market now. The industry as a whole is currently under the microscope of many investors. Obviously, this is due to the coronavirus pandemic that continue...

Vallon Pharmaceuticals has filed to raise $15 million in an IPO. The firm is developing reformulated treatments for ADHD and narcolepsy. VALL is a tiny and thinly capitalized firm. While I wish it well, I'll pass on the IPO. For further details see: IPO Update: Vallon Ph...

Now that the first approved coronavirus vaccines are rolling out worldwide, investors everywhere are scanning the horizon for signs of which biotech stock will be the next to hit it big. You've already heard about how Moderna impressed the world with the speed at which it developed its ...

2020 was a year of immense adversity and contrast, as stocks bounced back sharply from a pandemic-induced bear market. Biotechs play a pivotal role in managing down the pandemic as vaccine production ramps higher. January to provide further insights on multiple additional vaccine tria...

Looking For The Best Biotech Stocks to Watch In January? 3 Names To Know Biotech stocks have been one of the top-performing industries in the last few months. With the coronavirus spreading like wildfire, it is no surprise that biotech companies were at the frontlines in creatin...

Shares of Arcturus Therapeutics (NASDAQ: ARCT) were skyrocketing 40.9% higher as of 3:10 p.m. EST on Thursday. The huge gain came after Wells Fargo analyst Jim Birchenough initiated coverage on the stock with an overweight rating. He also set a $118 price target -- a premium of 139%...